BioGenes Reports Strong Growth of HCP Assay Development Business
News Feb 28, 2013
BioGenes GmbH announced a strong increase in sales volume in 2012, the year of the company’s 20th anniversary, due to a high demand of specific antibodies and ELISA assays used in drug development processes. In particular, the HCP assay development business showed a remarkable growth increasing by 36% over 2011.
BioGenes is a recognized partner of pharmaceutical companies all over the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.
“Our long-term strategy to focus on HCP assay development pays off and we expect the growth to continue at a similar pace in the months ahead,” said Dagmar Schwertner-Knoll, Marketing Director of BioGenes. “The next milestone is the development of pre-optimized HCP assay kits for more reliable host cell protein detection.”
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE
What Does the Future of Vaccines and Immunotherapy Look Like?News
Innovative biomaterials could enhance vaccines against HIV and other infectious diseases and immunotherapies for patients with cancer or dampen responses in autoimmune disorders, allergies and transplanted organ recipients. A review of these efforts was recently released.READ MORE
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE